Pharmacy and drug management leaders
Faster patient access, consistent decisions across clients, and less audit exposure.
Where to look: The lifecycle story and the decision record.
About
Why CliniVantIQ exists
CliniVantIQ takes a drug from the moment the FDA approval letter arrives to its place on the formulary, ready for claims and for the patients who need it. It watches the pipeline, classifies and routes every new product, supports the clinical, utilization management, and financial reviews that run in parallel, records every decision, and codes those decisions onto layered formularies that produce each client’s documents, search tools, and reports.
Who it is for
Built for the people who run drug management
Formulary management, drug list management, utilization management, clinical programs, P&T committee operations, and the financial decisions about where a drug sits on a formulary, at PBMs, health plans, and managed care organizations.
P&T and clinical pharmacists
Clinical defensibility, and less time assembling monographs.
Where to look: Cited drafts, and the fact that people make every decision.
Formulary and drug list managers
Complex coding, and many client drug lists to maintain.
Where to look: Flexible rules, layering, and outputs generated from one source.
Finance and value teams
Cost impact, and rebate and pricing exposure.
Where to look: Placement scenarios, pricing intelligence, and budget impact.
Executives
Risk, efficiency, and client service.
Where to look: Faster change cycles, and decisions anyone can trace.
What we believe
Built on three principles
Clear
We make complex clinical information simple. Every layout, sentence and chart should reduce effort for the reader.
Precise
We say exactly what we mean and back it with evidence. Numbers are sourced; claims are specific.
Human
Clinical work is about people. Patients are the reason this lifecycle exists, and we write and build that way.
Be first in line
Join the waitlist for early access, or book a 20-minute intro call if you're ready to talk now.
Launching mid December 2026. Join the waitlist for early access.